If you move prescription drugs in the United States — as a manufacturer, repackager, wholesale distributor, third-party logistics provider, or pharmacy — the grace period is over. The FDA's staggered exemptions from the Drug Supply Chain Security Act's enhanced drug distribution security requirements have expired for almost everyone, and 2026 is the first full year in which serialized, package-level traceability is simply the cost of doing business.

For the operators we talk to, the question is rarely "do we need to comply?" It's "what does DSCSA compliance software actually have to do, and how do we get there without blowing up our operations?" This guide answers both in plain English.

Where the DSCSA deadlines actually stand in 2026

The timeline has shifted enough times that a lot of good teams are working from outdated information. Here is the current picture, straight from the FDA:

• The one-year stabilization period following the November 2023 enhanced-requirements date ended on November 27, 2024.
• The FDA's follow-on exemptions then expired in tiers: May 27, 2025 for manufacturers and repackagers, August 27, 2025 for wholesale distributors, and November 27, 2025 for dispensers.
• Small dispensers — and, where applicable, their trading partners — remain exempt from certain section 582 requirements until November 27, 2027. A "small dispenser" is one whose owning company has 25 or fewer full-time employees licensed as pharmacists or qualified as pharmacy technicians, measured as of November 27, 2026.
• The FDA is encouraging small dispensers to complete its small dispensers assessment survey by September 22, 2026, and has been explicit that they should keep implementing rather than wait.

The practical takeaway: if you are anything other than a genuinely small pharmacy, you are already in scope. And if you are a small dispenser, you have roughly a year of runway — not a reprieve.

What the enhanced requirements mean in practice

Strip away the statutory language and DSCSA asks you to do five things reliably, every day, at package level.

1. Serialize and read unique product identifiers

Every saleable package carries a unique product identifier built from a GTIN, serial number, lot, and expiration date, encoded in a 2D DataMatrix. Your systems need to capture that identifier at receipt and shipment — not just the NDC and quantity.

2. Exchange traceability data electronically via EPCIS

Transaction information and transaction statements now move as structured EPCIS event data — GS1's standard for describing what happened to a product, where, when, and why. Emailed PDFs and spreadsheet-based advance ship notices no longer meet the bar. If a platform cannot send and receive standards-conformant EPCIS, it cannot sit in a compliant supply chain.

3. Verify products and saleable returns

You need the ability to send and answer verification requests against a product identifier — most commonly when a saleable return arrives, or when there is a suspicion of an illegitimate product.

4. Confirm authorized trading partner status

You may only transact with authorized trading partners, which means licensure and registration status has to be checked and recorded, not assumed.

5. Investigate suspect and illegitimate product

When data doesn't match — a serial number you never received, a duplicate, a discontinued lot — you need a documented quarantine, investigation, and notification workflow, including notifying the FDA where required.

The five capabilities to demand from DSCSA compliance software

Vendor demos all look similar. These are the areas where systems genuinely differ, and where we'd push hard during evaluation:

• Real EPCIS interoperability, both directions. Ask to see inbound files from three of your actual trading partners parsed successfully. Everyone's EPCIS is conformant until it meets someone else's.
• Exception management, not just data capture. In live operations, the work is the mismatches: short shipments, missing files, unreadable barcodes, returns without history. A platform that only stores clean data pushes the mess onto your team.
• Warehouse-floor usability. Scanning has to fit the pace of receiving and picking. If compliance adds thirty seconds per case, people find workarounds — and workarounds are where audit findings come from.
• ERP and WMS integration. Serialization data that lives in a separate portal, re-keyed by hand, is a permanent tax. It should flow into the systems your team already uses.
• Six years of retrievable records. DSCSA requires retention and reasonably prompt retrieval on request. "We have the data somewhere" is not the same as being able to produce a product's history during an investigation.

Buy, build, or connect?

Most companies land in one of three places, and the right answer depends far more on your operating model than on your size.

Buy a dedicated platform if your workflows are conventional and your volumes are typical. Established serialization vendors have solved the hard interoperability problems and maintain connections to a large network of trading partners. This is the fastest path to defensible compliance.

Connect with middleware if you already have a capable ERP or WMS and mainly need a translation layer — capturing scans, generating and ingesting EPCIS, and syncing with your system of record. This is often the best value for mid-size distributors and 3PLs who don't want to run two operational systems.

Build custom when your model is genuinely non-standard — unusual kitting or repackaging, a hybrid distribution and clinical operation, a marketplace with many small counterparties, or a compliance requirement you intend to turn into a product others can use. Custom work makes sense when compliance is entangled with a competitive advantage, not when it's a checkbox.

We'd add one honest caution: don't build to save money. Build because the off-the-shelf shape doesn't fit your business. If it does fit, buy it and spend your engineering budget somewhere that compounds.

A realistic implementation sequence

Teams that get this right tend to follow the same order. Start by mapping every physical touchpoint where product changes hands or location, then audit what data you actually receive today from each trading partner — this is usually where the surprises live. Pick your system, then run a parallel period where you process real receipts through both the new and old workflow before cutting over. Train on exceptions specifically, because that's the part nobody rehearses. Finally, document your quarantine and notification procedure before you need it; the middle of an investigation is a bad time to invent a process.

Compliance is the floor, traceability is the upside

Here's the part we care about most. Once you can identify a single package and reconstruct its journey, you have built the foundation for things the regulation never asked for: faster and narrower recalls, real visibility into diversion and gray-market leakage, cleaner returns reconciliation, and provable authenticity for your customers. The same serialization backbone that satisfies the FDA is the backbone of a modern brand protection program and of anti-counterfeiting technology across regulated and unregulated categories alike.

That reframing matters. A compliance project defended only as a cost gets underfunded and resented. The same project positioned as supply chain intelligence — with recall speed, shrink, and customer trust as the measures — tends to get built properly.

Where to start

At Esipick, we've spent more than a decade building traceability and product and go-to-market systems for founders and mid-size businesses, often for teams without an in-house engineering department. If you're weighing a platform against an integration against a custom build, an honest architecture conversation early will save you a painful migration later — and it's the kind of conversation we're glad to have whether or not you end up working with us.

You can explore how we approach AI-powered development and traceability at esipick.com, see what we're building on the AI side at esipick.ai, or simply book a call and walk us through your supply chain. We'll tell you plainly what we'd do in your position.

This article is general information about software and operational readiness, not legal or regulatory advice. Confirm your obligations and deadlines against current FDA guidance and with qualified counsel.